Literature DB >> 32073337

The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review.

Saifuddin Kharawala1, Amanda K Golembesky2, Rhonda L Bohn3, Dirk Esser4.   

Abstract

Introduction: Palmoplantar pustulosis (PPP) is a chronic, relapsing and refractory disease characterized by sterile pustules appearing on the palms and/or soles, accompanied by erythema, blistering, scales and/or keratinization. The overall burden of PPP in terms of its clinical impact, effect on patients and families, and economic consequences has not previously been investigated in a structured manner.Areas covered: A structured search focused on identification of studies in PPP using specific search terms in PubMed and EMBASE® from 2005 onwards, with additional back-referencing and pragmatic searches. Outcomes of interest included clinical burden, humanistic burden, and economic burden.Expert opinion: In cross-sectional studies, approximately 75% of all PPP patients suffer from active disease, with risk of relapse remaining constant over time. Patients' health-related quality of life is significantly impaired, as expected for a disease affecting hands and feet. Tools have been described that assess the clinical as well as patient-reported burden of PPP; their performance in larger cohorts and/or clinical trials remains to be investigated. The key data limitations identified include inconsistent definitions for characterizing remission/relapse, and limited humanistic and economic burden data; future studies are required to address these evidence gaps.

Entities:  

Keywords:  Clinical burden; comorbidities; economic burden; humanistic burden; mortality; palmoplantar pustulosis; prevalence; quality of life

Mesh:

Year:  2020        PMID: 32073337     DOI: 10.1080/1744666X.2019.1708194

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  3 in total

Review 1.  Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.

Authors:  Alan Menter; Abby S Van Voorhees; Sylvia Hsu
Journal:  Dermatol Ther (Heidelb)       Date:  2021-10-09

2.  Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.

Authors:  Yukari Okubo; Hitomi Morishima; Richuan Zheng; Tadashi Terui
Journal:  J Dermatol       Date:  2021-08-28       Impact factor: 3.468

3.  Generalized pustular psoriasis in Brazil: A public claims database study.

Authors:  Gleison Vieira Duarte; André Vicente Esteves de Carvalho; Ricardo Romiti; Antonio Gaspar; Thaís Gomes de Melo; Cinara Prata Soares; Anna Rita Aguirre
Journal:  JAAD Int       Date:  2022-01-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.